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Abstract
Background: Rising rates of infectious diseases in international migrants has reignited the debate around screening.
There have been calls to strengthen primary-care-based programmes, focusing on latent TB. We did a cross-sectional
study of new migrants to test an innovative one-stop blood test approach to detect multiple infections at one
appointment (HIV, latent tuberculosis, and hepatitis B/C) on registration with a General Practitioner (GP) in primary
care.
Methods: The study was done across two GP practices attached to hospital Accident and Emergency Departments
(A&E) in a high migrant area of London for 6 months. Inclusion criteria were foreign-born individuals from a high TB
prevalence country (>40 cases per 100,000) who have lived in the UK ≤ 10 years, and were over 18 years of age. All
new migrants who attended a New Patient Health Check were screened for eligibility and offered the blood test. We
followed routine care pathways for follow-up.
Results: There were 1235 new registrations in 6 months. 453 attended their New Patient Health Check, of which 47
(10.4%) were identified as new migrants (age 32.11 years [range 18–72]; 22 different nationalities; time in UK 2.28 years
[0–10]). 36 (76.6%) participated in the study. The intervention only increased the prevalence of diagnosed latent TB
(18.18% [95% CI 6.98-35.46]; 181.8 cases per 1000). Ultimately 0 (0%) of 6 patients with latent TB went on to complete
treatment (3 did not attend referral). No cases of HIV or hepatitis B/C were found. Foreign-born patients were
under-represented at these practices in relation to 2011 Census data (Chi-square test −0.111 [95% CI −0.125 to −0.097];
p < 0.001).
Conclusion: The one-stop approach was feasible in this context and acceptability was high. However, the number of
presenting migrants was surprisingly low, reflecting the barriers to care that this group face on arrival, and none
ultimately received treatment. The ongoing UK debate around immigration checks and charging in primary care
for new migrants can only have negative implications for the promotion of screening in this group. Until GP
registration is more actively promoted in new migrants, a better place to test this one-stop approach could be in
A&E departments where migrants may present in larger numbers.
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Background
International migrants have high levels of infectious dis-
ease, which has important implications for public health
services [1,2]. Approximately 70% of newly diagnosed
UK tuberculosis (TB) cases London are in migrants -
mainly as a result of reactivation of latent TB acquired
some years earlier - with most cases of active disease
presenting within 3–5 years of arrival [3,4]. TB rates in
the UK remain amongst the highest in western Europe
[5]. In addition, around 60% of HIV cases are in mi-
grants – mostly individuals from sub-Saharan Africa, of
which late presentation to health services remains an
important issue because of the barriers to health care
they face [3]. Comparable trends are expected for both
hepatitis B and C [3,6]. How best to improve the delivery
of cost-effective screening programmes for this often
hard-to-reach group remains the subject of ongoing de-
bate [7-9].
Screening approaches vary across UK and Europe [10],
with emphasis placed on identifying and treating active
TB on arrival in new entrants. In the UK, port of entry
tuberculosis x-ray screening of new arrivals has recently
been dismantled, amid calls to strengthen primary-care-
based screening programmes and to take a more pro-
active approach to screening in this group [3,7,8]. There
is a renewed focus being placed on latent TB screening
as a means of tackling high rates of active TB in the UK
at the current time, with evidence of cost-effectiveness
[11], yet there is considerable variability in approach to
latent TB screening UK-wide, and deviations from na-
tional guidelines [9,12]. Systematic screening for chronic
hepatitis B infection among migrants is likely to be cost
effective [13]. The National Institute for Health and
Clinical Excellence (NICE) has issued guidance to ensure
HIV testing is widely available in a range of healthcare
and community settings, including General Practitioner
(GP) practices [14]. Public Health England has recom-
mended an “extended” New Patient Health Check at
GP surgeries to explore broader health needs and to
tackle the barriers to health care that newly arrived mi-
grants face, as well as targeted TB screening and educa-
tion [3,15].
Whether GP practices offer a good opportunity to en-
gage newly arrived migrants in screening initiatives re-
mains unclear. In the UK, GPs act as gatekeepers to
services available on the National Health Service (NHS)
and so permanent registration with GPs on arrival to the
UK is essential to facilitating access. On the one hand
recent modelling work has shown that new migrants
present a substantial burden on primary care in the UK
[16], suggesting they present in large numbers, whereas
other studies indicate otherwise [17,18]. Migration status
is not routinely recorded at UK health services, making
data collection in this patient group challenging.
We undertook a cross-sectional study to test a new
screening intervention that offered new migrants (in the
UK ≤ 10 years) a one-stop blood test for HIV, latent TB,
and hepatitis B and C on registration with a GP in pri-
mary care. Our aim was to investigate whether the inter-
vention would increase the detection and treatment of
these diseases and to explore feasibility and acceptability
of this screening approach in the GP context.
Methods
The study was carried out in 2013 for a 6 month period
in two purposively selected primary care GP practices
located adjacent to hospital Accident and Emergency
Departments in a high migrant area of West London
(Hammersmith and Fulham), where 42.8% residents are
defined as foreign born/migrants according to the 2011
UK national population Census [19]. The survey site has
the tenth highest level of foreign-born nationals of all
local authorities in England and Wales, and is the eight
highest in terms of the proportion of foreign-born people
who have resided in the UK for less than 5 years [19].
Awareness-raising educational sessions were held for
all GP and practice staff prior to the start of the study,
and specific training carried out with the healthcare assist-
ant and practice nurses on research processes (including
participant recruitment and acquiring informed consent).
All new patients registering at these two practices were
given information about the study in 6 dominant local
languages (Arabic, English, Farsi, Gujarati, Polish, and
Somali) as part of their New Patient Registration Pack.
The existing procedure at these GP Practices, prior to
our study commencing, was to offer all new patients
who permanently register at either site a New Patient
Health Check. The New Patient Health Check is carried
out by the healthcare assistant or practice nurse once a
patient has permanently registered and includes a gen-
eral health check up and – more recently – an HIV test.
There is no formal screening programme in place for la-
tent TB, hepatitis B, and hepatitis C at these Practices;
such testing is done at the individual GP’s discretion.
Our aim, therefore, was to offer patients who met our
inclusion criteria additional testing for latent TB, hepa-
titis B, and hepatitis C at the New Patient Health Check.
We incorporated new questions into the template for
the INPS-Vision computer system (a standard system
used across UK primary care) to prompt staff to offer
the one-stop blood test to eligible patients and facilitate
routine data collection around migration status, an ap-
proach used successfully in a previous trial in the same
context [20]. Inclusion criteria were: (a) foreign-born in-
dividuals who have lived in the UK ≤ 10 years who, prior
to entry, had lived (≥1 years) in a country with a preva-
lence of TB above 40 cases per 100,000; (b) >18 years of
age; and (c) capable of giving informed consent.
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At the New Patient Health Check all eligible patients
were given time to read the participant information
sheet (available in Arabic, English, Farsi, Gujarati, Polish,
Somali). Telephone interpreters were available on request.
Of those who agreed to participate, written informed con-
sent was obtained. Participants were then offered the
blood test for latent TB, HIV, hepatitis B and C and blood
samples taken from participants. The tests used were
as follows: an interferon gamma release assay for TB
(QuantiFERON-TB [Quagen, Cellestis, Australia]), an
HIV screening assay and HIV confirmatory assay (HIV
combo assay and HIV Duo ultra, Abbott Architect and
Biomerieux Vidas), a hepatitis B Surface Antigen test
(Qualitative II Ultra, Abbott Architect, Biomerieux Vidas),
and a Hepatitis C antibody test (Anti HCV, Abbott Archi-
tect). Blood samples were paced in labelled study bags and
couriered daily to the local laboratory. We provided the
practices with the QuantiFERON-TB Gold In-Tubes. Rou-
tine care pathways were used for laboratory testing, com-
municating results, and for referral to follow-up care in
specialist services.
Prior to starting data collection, GP baseline data (de-
mographical data and baseline disease rates) were ex-
tracted through electronic searches of the INPS-Vision
system. Study data on eligible patients were anonymously
extracted from patient records every 2 weeks by the
healthcare assistant or practice nurse and shared with the
research team in an anonymous format. Data were ana-
lysed using STATA 12 (StataCorp). To avoid screening
bias, we compared demographical differences between pa-
tients who accepted and declined the intervention. The
study was approved by Bromley Research Ethics Commit-
tee, London, and follows STROBE guidelines [21].
Results
1618 of 5103 (31.7%) patients permanently registered at
the Practices were recorded as foreign-born/migrants
prior to the study starting; 2552 of 5103 (50.0%) were
Figure 1 TB, HIV, and hepatitis C cases according to patient’s region of origin in the general practices at baseline.
Figure 2 Flow chart of study.
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reported as from an ethnic minority group. Foreign-born
patients were significantly under-represented in com-
parison to 42.8% identified in 2011 Census data [19]
reporting the number of foreign-born people living in
the surrounding area (Chi-square test −0.111 [95% CI:
−0.125 to −0.097]; p < 0.001). From 2009–2012 prior to
the study starting, the majority of infectious diseases di-
agnosed in the permanently registered population was
among foreign-born in the two study sites (Figure 1).
This group had 10 cases of active TB (13 cases total
across the Practice) and 10 cases of HIV (13 total), giv-
ing a prevalence rate of active TB in the foreign-born
population of 6.2 cases per 1000 (0.62% [95% CI: 0.30 -
1.13]) and the prevalence rate of HIV in the foreign-
born population of 6.2 cases per 1000 (0.62% [95% CI:
0.30 - 1.13]). For hepatitis C, the prevalence rate was 0.6
cases per 1000 (0.06% [95% CI: 0.00 - 0.34]). No hepa-
titis B or latent TB was recorded as detected on the
INPS-Vision system.
During the study period 1235 new patients (both foreign
born and UK born) registered permanently, of which 453
(36.7%) attended a New Patient Health Check (Figure 2).
47 of 453 (10.4%) were identified as new migrants repre-
senting 22 nationalities (Table 1). 36 of 47 (76.6%) new
migrants agreed to participate in the study.
33 of 36 (91.6%) participants were screened using
QuantiFERON-TB (vasovagal attack in 1 patient; 1 sam-
ple lost in system; 1 not incubated in time), resulting in
a positive diagnosis in 6 (16.6%) patients. The prevalence
of diagnosed latent TB in new migrants at the survey
site was calculated at 181.8 cases per 1000 (18.18% [95%
CI 6.98-35.46]). No cases of HIV, hepatitis B, or hepatitis
C were found. During the study period, analysis of prac-
tice data showed an additional 3 cases of active TB (2
foreign and 1 UK born) and 1 case of HIV (foreign born)
diagnosed in patients across the practice who were not
included in the study. These diagnoses were made via
the patients individual GP, not through our intervention.
Of the 6 patients identified with latent TB, 3 did not
attend specialist clinic appointments, 2 were not eligible
for chemoprophylaxis under current UK NICE guide-
lines (they were older than 35 years), and the one patient
who was treated suffered an adverse drug reaction pre-
maturely ending therapy. The cost of the screening tests
per patient was UK £107.13 (USD$171.39), excluding
nurse time and transport costs.
Discussion and conclusions
Our intervention led to an increase in the prevalence of
diagnosed latent TB in comparison to baseline practice
data pre-intervention; however, none of these individuals
ultimately completed treatment. New migrants presented
to these two GP practices in surprisingly low numbers.
New migrants were relatively young, represented 22 di-
verse nationalities, and had been in the UK for short time-
periods (mean 2.28 years). The one-stop approach was
feasible in this context and acceptability was high (76.6%).
Despite the diverse backgrounds of presenting migrants,
their willingness to take the blood test was high, consist-
ent with previous work reporting that migrants are often
proactive about their health [22,23]. Qualitative research
we have carried out with migrant health-care leaders
around this survey site concluded that there is a great deal
of stigma surrounding infectious diseases within new mi-
grant communities, and barriers to accessing screening
[23]. Participants expressed support for a community-
focused package of health screening combining all of the
diseases into a general health check-up, with the aim of
reducing stigma around infectious disease screening [23].
Table 1 Demographic characteristics of new migrants identified in the study
Demographic All new migrant patients (n = 47) Agreed to intervention (n = 36) Declined intervention (n = 11)
Mean age (range) in years 32.11 years (18–72) 33.21(18–72) 29.64 (21–37)
Sex (M/F) 23/24 17/19 6/5
Mean years in the UK (range) 2.28 years (0–10) 2.36 (0–10) 2 (0–6)
Country of birth Asia (28) China (6) Hong Kong (1)
India (3) Iran (2) Malaysia (11)
Pakistan (1) Philippines (1) Thailand (2)
Yemen (1)
Asia (22) China (4) Hong Kong (1)
India (2) Iran (2) Malaysia (9) Pakistan (1)
Philippines (1) Thailand (2)
Asia (6)
China (2) India (1)
Malaysia (2) Yemen (1)
Africa (7) Libya (1) Morocco (1)
Nigeria (2) Somalia (2) South Africa (1)
Africa (6) Libya (1) Morocco (1)
Nigeria (2) Somalia (2)
Africa (1) South Africa (1)
Latin America (6) Argentina (1)
Colombia (3) Mexico (1) Peru (1)
Latin America (3) Colombia (2)
Argentina (1)
Latin America (3)
Columbia (1) Peru (1)
Mexico (1)
Eastern Europe (5) Bulgaria (1)
Lithuania (1) Poland (2) Romania (1)
Eastern Europe (4) Romania (1)
Poland (1) Bulgaria (1) Lithuania (1)
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A positive test for latent TB in 16.6% of new migrants
tested is comparable with a large multicentre cohort study
of IGRA screening in UK migrants [11] and concurs with
findings from a cluster randomised controlled trial screen-
ing for active TB and latent TB of all attendees at New
Patient Health Checks [20]. It is of concern that none
of the 6 latent TB cases identified in our study ultimately
received any treatment, with 3 (50%) of patients not at-
tending referral appointments at specialist secondary-care
services. Although numerous factors may explain low sec-
ondary care uptake in migrants, there are growing con-
cerns at the current time in the UK and Europe that
migrants increasingly fear approaching chargeable second-
ary services where they may incur immigration checks
and potentially unaffordable health-care costs [24]. Des-
pite the fact that screening and treatment for infectious
diseases remains free of charge, the current tendency to-
wards a more restrictive approach to health care access
based on financial and other penalties can only have nega-
tive implications for the promotion of screening and pre-
vention in newly arrived migrants.
Despite the fact that the survey site was in a high mi-
grant area, new migrants presented in surprisingly low
numbers, with foreign-born nationals significantly under-
represented in relation to local survey data. This is
consistent with other data that suggests migrants are
somehow being discouraged from registering with primary-
care providers [17]. New migrants with low levels of
English may also be less aware of New Patient Health
Checks and procedures for GP registration. Our data,
therefore, run contrary to current discourse in the UK
around the disproportionate impact of migrants on
primary-care services [16,25]. We note, however, that
there are limitations to our comparison of numbers of
foreign-born patients in the practice, versus those in
the community, because these data are based on latest
Census data available at the time (from 2011) and migra-
tion patterns may have changed when data collection at
the Practices began.
The one-stop blood test approach is feasible to do in
the primary-care context, with healthcare assistants/
practice nurses able to engage new migrants in screening
at the New Patient Health Check appointment, facilitate
laboratory testing and the follow-up/communication of
results, and to record basic data on migration status onto
the GP INPS-Vision system. However, further data and
cost-effectiveness analyses are needed to better under-
stand how the one-stop blood test model can be best used.
Until more emphasis is placed on actively promoting
primary-care access for newly arrived migrants, including
a proactive approach to encouraging them to register with
a GP and attend a New Patient Health Check, General
Practice may not be the appropriate place to focus screen-
ing interventions for multiple diseases in new migrants.
A more successful approach may be to offer one-stop
screening in Accident and Emergency Departments in
secondary care where migrants may present in large num-
bers [26], or to facilitate active case-finding in the commu-
nity linked to a robust system that ensures individuals
receive treatment at specialist services.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SH and JSF devised the study with support from JC, SH, and RE. FS and SH
carried out the study, with FS leading on the day-to-day running of the
study and data collection. FS and JE analysed the data and did the statistical
analysis. FS, SH, and JSF interpreted the data. FS and SH wrote a draft of the
paper and all authors inputted into the final article and have seen and approved
a final version for publication.
Acknowledgement
This work was funded by the Imperial College Healthcare Charity and the
Imperial Biomedical Research Centre.
Author details
1Imperial College London, Department of Medicine, Section of Infectious
Diseases and Immunity, Hammersmith Hospital Campus, 8th Floor
Commonwealth Building, DuCane Road, London W12 ONN, UK.
2Hammersmith and Fulham Centres for Health, Hammersmith Hospital,
Hammersmith, London.
Received: 4 July 2014 Accepted: 24 November 2014
References
1. Rechel B, Mladovsky P, Ingleby D, Mackenbach JP, McKee M: Migration and
health in an increasingly diverse Europe. Lancet 2013, 381(9873):1235–1245.
2. Hargreaves S, Friedland JS: Impact On and Use of Health Services by New
Migrants in Europe. In Migration, Health and Inequality. Edited by Thomas F,
Gideon J. London: Zed Books; 2013.
3. HPA: Migrant Health: Infectious Diseases in Non-UK Born Populations in England,
Wales, and Northern Ireland. An Update to the Baseline Report - 2011. London:
Health Protection Agency Centre for Infections; 2011.
4. Public Health England: Tuberculosis in the UK: Annual Report on Tuberculosis
Surveillance in the UK, 2013. London: Public Health England; 2013.
5. European Centre for Disease Prevention and Contro: Tuberculosis Surveillance
and Monitoring in Europe 2013. Stockholm: ECDC; 2013.
6. Hahne SJM, Veldhuijzen IK, Wiessing L, Lim T-A, Salminen M, van de Laar M:
Infection with hepatitis B and C virus in Europe: a systematic review of
prevalence and cost-effectiveness of screening. BMC Infect Dis 2013,
13:181.
7. Hargreaves S, Carballo M, Friedland JS: Screening migrants for tuberculosis -
where next? Lancet Infect Dis 2009, 9:139–140.
8. Bothamley GH, Rowan JP, Griffiths CJ, Beeks M, McDonald M, Beasley E, van
den Bosch C, Feder G: Screening for tuberculosis: the port of arrival
scheme compared with screening in general practice and the homeless.
Thorax 2002, 57:45–49.
9. Ormerod LP: Further evidence supporting programmatic screening for,
and treatment of latent TB Infection (LTBI) in new entrants to the UK
from high TB prevalence countries. Thorax 2013, 68:201.
10. Pareek M: Evaluation of immigrant tuberculosis screening in industrialize
countries. Emerg Infect Dis 2012, 18(9):1422–1429.
11. Pareek M, Watson JP, Ormerod LP, Kon OM, Woltmann G, White PJ,
Abubakar I, Lalvani A: Screening of immigrants in the UK for imported
latent tuberculosis: a multicentre cohort study and cost-effectiveness
analysis. Lancet 2011, 11:435–444.
12. Pareek M: Tuberculosis screening of migrants to low-burden nations:
insights from evaluation of UK practice. Eur Respir J 2011, 37(5):1175–1182.
13. Veldhuijzen IK, Toy M, Hahne SJM, de Wit GA, Richardus JH: Screening and
early treatment of migrants for chronic hepatitis B virus infection is cost-
effective. Gastroenterology 2010, 13(2):522–530.
Hargreaves et al. BMC Infectious Diseases 2014, 14:657 Page 5 of 6
http://www.biomedcentral.com/1471-2334/14/657
14. NICE: Increasing the Uptake of HIV Testing Among Black Africans in England.
London: NICE; 2011.
15. Public Health England: Collaborative TB Strategy for England: 2014–2019. For
Consultation. London: PHE; 2014.
16. Prederi: Quantitative Assessment of Visitor and Migrant Use of the NHS in
England. Exploring the Data. Summary Report. London: Prederi; 2013.
17. Stagg HR, Jones J, Bickler G, Abubakar I: Poor uptake of primary healthcare
registration among recent entrants to the UK: a retrospective cohort
study. BMJ Open 2012, 2:e001453. doi: 10.1136/bmjopen-2012-001453.
18. Hargreaves S, Holmes AH, Saxena S, Eliahoo J, Friedland JS: Charging
systems for migrants in primary care: the experiences of family doctors
in a high-migrant area of London. J Travel Med 2008, 15:13–18.
19. Office for National Statistics: Census: Aggregate Data (England and Wales);
2011. Downloaded from: http://infuse.mimas.ac.uk.
20. Griffiths C, Sturdy P, Brewin P, Bothamley G, Eldridge S, Martineau A,
MacDonald M, Ramsay J, Tibrewal S, Levi S, Zumla A, Feder G: Educational
outreach to promote screening for tuberculosis in in primary care:
a cluster randomised controlled trial. Lancet 2007, 369(9572):1528–1534.
21. STROBE Statement - Checklist of Items That Should Be Included in Reports of
Cross-Sectional Studies. http://www.strobe-statement.org/fileadmin/Strobe/
uploads/checklists/STROBE_checklist_v4_cross-sectional.pdf.
22. Brewin P, Jones A, Kelly M, McDonald M, Beasley E, Sturdy P, Bothamley G,
Griffiths C: Is screening for tuberculosis acceptable to immigrants?
A qualitative study. J Public Health 2006, 28:253–260.
23. Seedat F, Hargreaves S, Friedland JS: Engaging new migrants in infectious
disease screening: a qualitative semi-structured in-depth interview
study of UK migrant community health-care leads. PLoS One 2014,
9(10):e108261. doi:10.1371/journal.pone.0108261.
24. Thomas F, Aggleton P, Anderson J: “If I cannot access services, then there
is no reason for me to test”: the impacts of health service charges on
HIV testing and treatment amongst migrants in England. AIDS CARE 2010,
22(4):526–531.
25. DoH. Visitor and Migrant NHS Cost Recovery Programme: Sustaining Services
and Ensuring Fairness in the NHS. Implementation Outline. London: DoH; 2014.
26. Hargreaves S, Friedland JS, Gothard P, Saxena S, Millington H, Eliahoo J, Le
Feuvre P, Homes A: Impact on and use of health services by international
migrants: questionnaire survey of inner city London A&E attenders. BMC Hlth
Serv Res 2006, 6:153–158. http://www.biomedcentral.com/1472-6963/6/153.
doi:10.1186/s12879-014-0657-2
Cite this article as: Hargreaves et al.: Screening for latent TB, HIV, and
hepatitis B/C in new migrants in a high prevalence area of London, UK:
a cross-sectional study. BMC Infectious Diseases 2014 14:657.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Hargreaves et al. BMC Infectious Diseases 2014, 14:657 Page 6 of 6
http://www.biomedcentral.com/1471-2334/14/657
